vs
CRYO CELL INTERNATIONAL INC（CCEL）与Progyny, Inc.（PGNY）财务数据对比。点击上方公司名可切换其他公司
Progyny, Inc.的季度营收约是CRYO CELL INTERNATIONAL INC的40.6倍（$318.4M vs $7.8M）。Progyny, Inc.净利率更高（3.9% vs -48.7%，领先52.6%）。Progyny, Inc.同比增速更快（6.7% vs -2.3%）。Progyny, Inc.自由现金流更多（$48.6M vs $1.2M）。过去两年Progyny, Inc.的营收复合增速更高（7.0% vs -0.1%）
Cryo-Cell国际是一家脐带血库企业，由丹·理查德于1989年创立，是全球首家分离并储存干细胞的民营脐带血库，总部位于佛罗里达州奥兹马尔，地处坦帕市郊。
Progyny, Inc.是总部位于美国的领先生育与家庭构建福利服务商，主要与企业雇主合作，提供试管婴儿、生育力保存、收养协助、代孕支持等综合生育相关福利方案，覆盖多个行业的雇员群体。
CCEL vs PGNY — 直观对比
营收规模更大
PGNY
是对方的40.6倍
$7.8M
营收增速更快
PGNY
高出9.0%
-2.3%
净利率更高
PGNY
高出52.6%
-48.7%
自由现金流更多
PGNY
多$47.4M
$1.2M
两年增速更快
PGNY
近两年复合增速
-0.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.8M | $318.4M |
| 净利润 | $-3.8M | $12.5M |
| 毛利率 | 77.9% | 24.1% |
| 营业利润率 | -50.6% | 4.8% |
| 净利率 | -48.7% | 3.9% |
| 营收同比 | -2.3% | 6.7% |
| 净利润同比 | -105.1% | 18.5% |
| 每股收益（稀释后） | $-0.46 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCELPGNY
| Q4 25 | $7.8M | $318.4M | ||
| Q3 25 | $7.8M | $313.3M | ||
| Q2 25 | $7.9M | $332.9M | ||
| Q1 25 | $8.0M | $324.0M | ||
| Q4 24 | $8.0M | $298.4M | ||
| Q3 24 | $8.1M | $286.6M | ||
| Q2 24 | $8.0M | $304.1M | ||
| Q1 24 | $7.9M | $278.1M |
净利润CCELPGNY
| Q4 25 | $-3.8M | $12.5M | ||
| Q3 25 | $749.4K | $13.9M | ||
| Q2 25 | $355.8K | $17.1M | ||
| Q1 25 | $282.9K | $15.1M | ||
| Q4 24 | $-1.9M | $10.5M | ||
| Q3 24 | $1.1M | $10.4M | ||
| Q2 24 | $655.8K | $16.5M | ||
| Q1 24 | $556.2K | $16.9M |
毛利率CCELPGNY
| Q4 25 | 77.9% | 24.1% | ||
| Q3 25 | 77.0% | 23.2% | ||
| Q2 25 | 76.6% | 23.7% | ||
| Q1 25 | 75.1% | 23.4% | ||
| Q4 24 | 78.4% | 21.3% | ||
| Q3 24 | 73.6% | 20.7% | ||
| Q2 24 | 74.8% | 22.5% | ||
| Q1 24 | 73.7% | 22.4% |
营业利润率CCELPGNY
| Q4 25 | -50.6% | 4.8% | ||
| Q3 25 | 24.3% | 6.9% | ||
| Q2 25 | 18.8% | 7.3% | ||
| Q1 25 | 13.3% | 7.5% | ||
| Q4 24 | -1.5% | 5.3% | ||
| Q3 24 | 17.2% | 4.3% | ||
| Q2 24 | 17.3% | 6.8% | ||
| Q1 24 | 10.5% | 6.7% |
净利率CCELPGNY
| Q4 25 | -48.7% | 3.9% | ||
| Q3 25 | 9.6% | 4.4% | ||
| Q2 25 | 4.5% | 5.1% | ||
| Q1 25 | 3.5% | 4.6% | ||
| Q4 24 | -23.2% | 3.5% | ||
| Q3 24 | 13.0% | 3.6% | ||
| Q2 24 | 8.2% | 5.4% | ||
| Q1 24 | 7.1% | 6.1% |
每股收益（稀释后）CCELPGNY
| Q4 25 | $-0.46 | $0.14 | ||
| Q3 25 | $0.09 | $0.15 | ||
| Q2 25 | $0.04 | $0.19 | ||
| Q1 25 | $0.03 | $0.17 | ||
| Q4 24 | $-0.23 | $0.12 | ||
| Q3 24 | $0.13 | $0.11 | ||
| Q2 24 | $0.08 | $0.17 | ||
| Q1 24 | $0.07 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.3M | $112.2M |
| 总债务越低越好 | $8.4M | — |
| 股东权益账面价值 | $-18.6M | $516.0M |
| 总资产 | $61.7M | $742.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCELPGNY
| Q4 25 | $3.3M | $112.2M | ||
| Q3 25 | $3.2M | $134.0M | ||
| Q2 25 | $4.4M | $132.5M | ||
| Q1 25 | $3.5M | $109.2M | ||
| Q4 24 | $3.5M | $162.3M | ||
| Q3 24 | $2.1M | $91.5M | ||
| Q2 24 | $1.5M | $95.0M | ||
| Q1 24 | $979.6K | $115.0M |
总债务CCELPGNY
| Q4 25 | $8.4M | — | ||
| Q3 25 | $8.4M | — | ||
| Q2 25 | $8.4M | — | ||
| Q1 25 | $8.5M | — | ||
| Q4 24 | $8.5M | — | ||
| Q3 24 | $8.5M | — | ||
| Q2 24 | $8.5M | — | ||
| Q1 24 | $8.6M | — |
股东权益CCELPGNY
| Q4 25 | $-18.6M | $516.0M | ||
| Q3 25 | $-14.8M | $560.0M | ||
| Q2 25 | $-15.6M | $515.0M | ||
| Q1 25 | $-14.7M | $467.2M | ||
| Q4 24 | $-13.2M | $422.1M | ||
| Q3 24 | $-9.6M | $434.9M | ||
| Q2 24 | $-10.7M | $456.2M | ||
| Q1 24 | $-10.3M | $571.6M |
总资产CCELPGNY
| Q4 25 | $61.7M | $742.4M | ||
| Q3 25 | $63.2M | $795.2M | ||
| Q2 25 | $64.4M | $761.0M | ||
| Q1 25 | $64.4M | $730.3M | ||
| Q4 24 | $64.7M | $607.1M | ||
| Q3 24 | $62.9M | $660.0M | ||
| Q2 24 | $62.6M | $698.6M | ||
| Q1 24 | $61.7M | $794.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3M | $54.2M |
| 自由现金流经营现金流 - 资本支出 | $1.2M | $48.6M |
| 自由现金流率自由现金流/营收 | 15.5% | 15.3% |
| 资本支出强度资本支出/营收 | 0.9% | 1.8% |
| 现金转化率经营现金流/净利润 | — | 4.34× |
| 过去12个月自由现金流最近4个季度 | $5.2M | $191.8M |
8季度趋势，按日历期对齐
经营现金流CCELPGNY
| Q4 25 | $1.3M | $54.2M | ||
| Q3 25 | $2.5M | $50.7M | ||
| Q2 25 | $707.0K | $55.5M | ||
| Q1 25 | $954.1K | $49.8M | ||
| Q4 24 | $2.2M | $52.2M | ||
| Q3 24 | $2.4M | $44.5M | ||
| Q2 24 | $1.8M | $56.7M | ||
| Q1 24 | $-356.9K | $25.7M |
自由现金流CCELPGNY
| Q4 25 | $1.2M | $48.6M | ||
| Q3 25 | $2.5M | $46.0M | ||
| Q2 25 | $644.6K | $50.2M | ||
| Q1 25 | $892.0K | $47.0M | ||
| Q4 24 | $2.1M | $50.3M | ||
| Q3 24 | $2.3M | $42.7M | ||
| Q2 24 | $21.5K | $55.8M | ||
| Q1 24 | $-814.6K | $24.9M |
自由现金流率CCELPGNY
| Q4 25 | 15.5% | 15.3% | ||
| Q3 25 | 31.9% | 14.7% | ||
| Q2 25 | 8.1% | 15.1% | ||
| Q1 25 | 11.2% | 14.5% | ||
| Q4 24 | 26.8% | 16.8% | ||
| Q3 24 | 27.9% | 14.9% | ||
| Q2 24 | 0.3% | 18.4% | ||
| Q1 24 | -10.4% | 8.9% |
资本支出强度CCELPGNY
| Q4 25 | 0.9% | 1.8% | ||
| Q3 25 | 0.5% | 1.5% | ||
| Q2 25 | 0.8% | 1.6% | ||
| Q1 25 | 0.8% | 0.9% | ||
| Q4 24 | 0.1% | 0.6% | ||
| Q3 24 | 2.3% | 0.6% | ||
| Q2 24 | 21.8% | 0.3% | ||
| Q1 24 | 5.8% | 0.3% |
现金转化率CCELPGNY
| Q4 25 | — | 4.34× | ||
| Q3 25 | 3.38× | 3.65× | ||
| Q2 25 | 1.99× | 3.24× | ||
| Q1 25 | 3.37× | 3.31× | ||
| Q4 24 | — | 4.95× | ||
| Q3 24 | 2.32× | 4.27× | ||
| Q2 24 | 2.70× | 3.44× | ||
| Q1 24 | -0.64× | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCEL
暂无分部数据
PGNY
| Fertility Benefit Services | $208.6M | 66% |
| Pharmacy Benefit Services | $109.8M | 34% |
